Switching patients to fixed-dosing aflibercept after as-needed treatment with ranibizumab or bevacizumab resulted in visual gain and reduction of central subfoveal thickness in a trial. However, benefits were lost through undertreatment when patients returned to routine clinical practice after release from the trial.
Within the ASSESS prospective trial performed at Cole Eye Institute, 32 patients with age-related macular degeneration were transitioned from Avastin (bevacizumab, Genentech) or Lucentis (ranibizumab, Genentech) to fixed bimonthly intravitreal Eylea (aflibercept, Regeneron)
Uncategorized